Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
Kana N. Miyata, Chao‐Sheng Lo, Shuiling Zhao, et al.
Clinical Science (2021) Vol. 135, Iss. 7, pp. 943-961
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 124
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 37
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Asmaa Elrakaybi, Katharina Laubner, Qian Zhou, et al.
Molecular Metabolism (2022) Vol. 64, pp. 101549-101549
Open Access | Times Cited: 56
Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives
Yu Wang, Mingyue Jin, Chak Kwong Cheng, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 41
Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, et al.
Pharmacological Research (2023) Vol. 188, pp. 106659-106659
Open Access | Times Cited: 37
Sodium–glucose cotransporter‐2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies
Jan Biegus, Marat Fudim, Husam M. Salah, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1526-1536
Open Access | Times Cited: 23
The Role of SGLT2-Inhibitors Across All Stages of Heart Failure and Mechanisms of Early Clinical Benefit: From Prevention to Advanced Heart Failure
Simone Pasquale Crispino, Andrea Segreti, Vincenzo Nafisio, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 608-608
Open Access | Times Cited: 1
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 46
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting
Hui Lin, Frank Geurts, Luise Hassler, et al.
Pharmacological Reviews (2022) Vol. 74, Iss. 3, pp. 462-505
Open Access | Times Cited: 37
SGLT2 Inhibition and Kidney Potassium Homeostasis
Biff F. Palmer, Deborah J. Clegg
Clinical Journal of the American Society of Nephrology (2023) Vol. 19, Iss. 3, pp. 399-405
Open Access | Times Cited: 19
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets
Paschalis Karakasis, Panagiotis Theofilis, Panayotis K. Vlachakis, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 209-209
Open Access | Times Cited: 8
Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms
Chengren Xu, Xiaowen Ha, Shufen Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 15
SGLT2 Inhibitor—Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism
Batoul Dia, Sahar Alkhansa, Rachel Njeim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 965-965
Open Access | Times Cited: 11
The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI
Francesco Trepiccione, Anna Iervolino, Mariavittoria D’Acierno, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 720
Closed Access | Times Cited: 11
SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
Xiaochun Zeng, Yuan Tian, Xianming Liang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
Renal Tubule-Specific Angiotensinogen Deletion Attenuates SGLT2 Expression and Ameliorates Diabetic Kidney Disease in Murine Models of Type 1 Diabetes
Wenxia Yang, Ke Su, Min-Chun Liao, et al.
Diabetes (2025)
Closed Access
Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Kidney Disease and Beyond
Zein Alabdin Hannouneh, Carmen Elena Cervantes, Mohamad Hanouneh, et al.
Glomerular Diseases (2025) Vol. 5, Iss. 1, pp. 119-132
Open Access
Epigallocatechin gallate (EGCG) alleviates vascular dysfunction in angiotensin II-infused hypertensive mice by modulating oxidative stress and eNOS
Nurul Aiza Mohd Sabri, Siew-Keah Lee, D. Murugan, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
Xiutian Chen, Jiali Wang, Yongda Lin, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3913-3913
Open Access | Times Cited: 17
Non-Haemodynamic Mechanisms Underlying Hypertension-Associated Damage in Target Kidney Components
Elisa Russo, Elisabetta Bussalino, Lucia Macciò, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9422-9422
Open Access | Times Cited: 9
Dapagliflozin: A sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling
Ge Zhan, X Wang, Xin Wang, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176712-176712
Open Access | Times Cited: 3
Assessment of protective effect of the losartan against cisplatin-induced nephrotoxicity in mice
Selçuk Teke, Gülşen Bayrak, Erdem Ak, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease
Mette V. Østergaard, Thomas Secher, Michael Christensen, et al.
AJP Renal Physiology (2021) Vol. 321, Iss. 2, pp. F149-F161
Closed Access | Times Cited: 23
RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor
Fangyan Tan, Xianglin Long, Jianlin Du, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 166, pp. 115289-115289
Open Access | Times Cited: 9
Is the proximal tubule the focus of tubulointerstitial fibrosis?
Zhi Peng, Hui Wang, Jiaoyun Zheng, et al.
Heliyon (2023) Vol. 9, Iss. 2, pp. e13508-e13508
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top